Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

parathyroid hormone

- PMLiVE

J&J files ‘breakthrough’ drug ibrutinib in US

FDA to assess drug in lymphoma and leukaemia

Novartis sponsors rare disease patient community

Backs site for patients affected by pancreatic neuroendocrine tumours (PNET)

- PMLiVE

GSK files combination skin cancer drug in US

Seeks FDA approval for Tafinlar - Mekinist combination in melanoma

- PMLiVE

Novartis enters developing nations vaccines partnership

Will work with Biological E to deliver vaccines for typhoid and paratyphoid A fevers

Novartis building

Novartis’ secukinumab tops Enbrel in psoriasis study

Phase III results show the antibody is more effective than Amgen/Pfizer's blockbuster

Novartis day

Lucentis cleared in Europe for pathological myopia

Makes Novartis' drug the first anti-VEGF approved in this setting

Croatia joins European medicines network

Follows country's membership of the European Union

- PMLiVE

GSK’s personalised cancer drug Tafinlar set for European approval

Regulatory advisors recommend the melanoma drug be licensed

- PMLiVE

First mAb biosimilars set for European approval

Celltrion and Hospira's versions of J&J's blockbuster Remicade recommended by CHMP

- PMLiVE

Novartis and Savient face NICE rejections

Jakavi and Krystexxa turned down for NHS use in England and Wales

Novartis building

Novartis’ omalizumab on track for filing in serious skin disease

Is active ingredient in asthma drug Xolair

- PMLiVE

Sandoz takes short route for biosimilar Enbrel approval

Novartis subsidiary initiates late-stage trial to support use in chronic plaque-type psoriasis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links